Monoclonal Antibody Reduces Symptomatic COVID-19 Risk by 84% in Immunocompromised
Published: August 27th 2024 | Updated: August 27th 2024Invivyd’s investigational pemivibart (Pemgarda), which received an FDA emergency use authorization earlier this year, continued to show efficacy in preventing disease onset over a 6-month exploratory period in this patient population.
The Benefits of Making C diff a Nationally Notifiable Infectious Disease
August 26th 2024In the second part of our interview with Christian Lillis, cofounder and CEO of the Peggy Lillis Foundation, he discusses what the passage of the Peggy Lillis Clostridioides difficile Inclusion Act would do for reporting of the infection as well as the potential ancillary effects around antibiotic development and antimicrobial resistance.
Top 5 Infectious Disease News Stories Week of August 16-August 23
August 24th 2024This week, Pfizer-BioNTech's Phase 3 trial of a COVID-19 and influenza combination vaccine yielded mixed results, mpox as a global health emergency emphasizes need for coordinated international response, ongoing challenges with MRSA infections, and more
Mpox Vaccine Manufacturer is Prepared to Increase Production
August 19th 2024Bavarian Nordic is working to get their MVA-BN (Jynneos) mpox vaccine to those affected in African countries, as well as working towards a clinical trial for the younger pediatric population, and potential regulatory approval in Europe for adolescents.
Navigating Mpox's Immune Evasion and Its Impact on Public Health and Therapy
August 19th 2024Mpox virus evades the innate immune system by interfering with antiviral pathways signaling and interferon responses, increasing replication, and complicating outbreak management, especially in non-endemic regions.